Arginine methylation modification in the malignant progression of benign and malignant liver diseases  

作　　者：Jie-Zuo Huang Bei-Ning Qiao Dang-Chi Li Qiu-Rong Wei Zi-Jian Zhang 

机构地区：[1]College of Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,China [2]Department of Ecology and Evolutionary Biology,University of California,Los Angeles,612,Charles E.Young Drive East,Los Angeles 90095,CA,USA [3]Department of Pediatrics,Chibi People’s Hospital,Xianning 437300,China [4]Department of Oncology,Xiangya Hospital,Central South University,Changsha 410008,China [5]National Clinical Research Center of Geriatric Disorders,Xiangya Hospital,Central South University,Changsha 410008,China

出　　处：《iLIVER》2024年第4期7-14,共8页国际肝胆健康(英文)

基　　金：financially supported by the Natural Science Foundation of Hunan Province,China(Grant No.2023JJ50014).

摘　　要：The role of protein arginine methyltransferases(PRMTs)in benign and malignant liver diseases has garnered considerable attention.PRMTs play a key function in regulating protein methylation modification in diseases such as alcoholic fatty liver disease,metabolic dysfunction–associated steatotic liver disease,viral hepatitis,and hepatocellular carcinoma.This review explores the mechanisms of action of PRMTs in these diseases,with a focus on their effects on cell signaling,transcriptional regulation,cell proliferation,and metabolism.We also discuss potential therapeutic strategies targeting PRMTs and propose future research directions.This review helps deepen the understanding of the important role of arginine methylation modification in the malignant progression of liver diseases and provides guidance for future clinical treatment and drug development.

关 键 词：METABOLISM Therapeutic strategies Arginine methyltransferases Liver diseases Alcoholic liver disease Non-alcoholic liver disease Metabolic dysfunction–associated steatotic liver disease Viral hepatitis Hepatocellular carcinoma 

分 类 号：R73[医药卫生—肿瘤]